FDA OKs Ustekinumab (Stelara) for Moderate to Severe UC FDA OKs Ustekinumab (Stelara) for Moderate to Severe UC
Ustekinumab was more effective than placebo for inducing and maintaining remission and promoting mucosal healing in a study of adults with moderately to severely active ulcerative colitis.FDA Approvals
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Gastroenterology News Alert Source Type: news
More News: Gastroenterology | Inflammatory Bowel Disease | Internal Medicine | Stelara | Study | Ulcerative Colitis